Halozyme Therapeutics Inc (HALO) — closed signal from May 12, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 10, 2026.
Predicted vs. what happened
HALO price · publication thesis → realized outcomesplit-adjusted
$66.00 – $70.50Entry zone — fair-value band
$70.47Published — price the day we called it
$82.44Target — the price the thesis aimed for
$104.77Peak — highest point inside the window, not a realized return
$102.62Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 73 days.
Peak price
$104.77
peak on August 10, 2026 — not a realized returnPeak gain
+48.7%
peak, from the publication priceWindow close
$102.62
end-of-window price, context onlyDays to target
73
Window
May 12, 2026 – August 10, 2026
The thesis — published May 12, 2026
Predicted growth
+17%
over the measurement windowTarget price
$82.44
the price the thesis aimed forEntry zone
$66.00 – $70.50
the fair-value band we waited forPrice at publication
$70.47
published May 12, 2026Confidence
71%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Halozyme just reported strong results, repeated guidance, and announced a big share buyback while saying ENHANZE royalties should rise. That mix makes cash returns and sales visibility look better. The stock has already run up, with heavy short interest and overbought signals, so upside near-term may be limited until the price settles.
Primary drivers
- Rising ENHANZE royalties make future sales more visible
- Large buyback increases cash returned to shareholders
- A recent quarterly beat shows improving business momentum
- Healthy cash reduces risk from relying on royalties
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.